Cargando…
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study
Daily granulocyte colony-stimulating factors [(G-CSFs); e.g. filgrastim, lenograstim] are frequently used to reduce the duration of chemotherapy-induced neutropenia (CIN) and the incidence of febrile neutropenia (FN) in cancer patients. A pegylated formulation of filgrastim, pegfilgrastim, which is...
Autores principales: | ALMENAR, D, MAYANS, J, JUAN, O, BUENO, JM GARCIA, LOPEZ, JI JALON, FRAU, A, GUINOT, M, CEREZUELA, P, BUSCALLA, E GARCIA, GASQUET, JA, SANCHEZ, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702003/ https://www.ncbi.nlm.nih.gov/pubmed/19076208 http://dx.doi.org/10.1111/j.1365-2354.2008.00959.x |
Ejemplares similares
-
Recurrent Granulocyte Colony-Stimulating Factor-Induced Aortitis After Pegfilgrastim Administration
por: Kawahara, Hiroshi, et al.
Publicado: (2020) -
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor
por: Arvedson, Tara, et al.
Publicado: (2015) -
Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012) -
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009) -
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)